The MedsBase Diabetes parent catalogue groups all diabetes-related medications across the major drug classes. The detailed clinical breakdown by molecule family with full brand listing is in our Diabetes Medication sub-category — please browse there for selection guidance and dosing context. All products are supplied by WHO-GMP certified manufacturers.
Drug-class summary. Biguanides (metformin — first-line, Glycomet SR, Metford), sulfonylureas (gliclazide, glimepiride, glibenclamide, glipizide), DPP-4 inhibitors (sitagliptin Januvia, vildagliptin Galvus, saxagliptin Onglyza, linagliptin Trajenta, teneligliptin Ziten), SGLT-2 inhibitors (dapagliflozin Forxiga, empagliflozin Jardiance, canagliflozin Invokana — with cardio-renal protection benefits), pioglitazone (Pioz), meglitinides (repaglinide Novonorm, nateglinide Glinate), alpha-glucosidase inhibitors (acarbose Glucobay, voglibose Voglibite, miglitol Mignar), and rapid-acting insulin pens (insulin aspart Novorapid Flexpen, insulin glulisine Apidra SoloStar). Combination therapies pairing metformin with sulfonylurea, DPP-4 inhibitor, or SGLT-2 inhibitor reduce pill burden in poly-pharmacy patients.
Specialty agents. Lipaglyn (saroglitazar — dual PPAR α/γ agonist for diabetic dyslipidaemia and NASH) as Lipaglyn. Methycobalamin / cyanocobalamin injections for diabetic neuropathy as Methycobal Injection.
What is NOT here. GLP-1 receptor agonists (semaglutide Ozempic, liraglutide Victoza, dulaglutide, tirzepatide) are stocked separately as part of our weight-management ordering — see Best Ozempic Alternatives 2026. Long-acting basal insulins (insulin glargine, degludec, detemir) are listed in dedicated insulin sub-categories where in stock.
Disambiguation. Desmopressin (Minirin tablet, Minirin Nasal Spray) is currently mis-listed in our diabetes catalogue. Desmopressin treats diabetes insipidus (a kidney disorder of water handling) and bedwetting / nocturia — NOT diabetes mellitus (the common type 1 / type 2 diabetes). Pages explicitly clarify this. Please move to the bladder-prostate / urology category once a dedicated bedwetting category exists.
How to choose. Type 2 diabetes new diagnosis → metformin first-line (titrate to 1.5–2 g/day in divided doses). Inadequate control on metformin → add SGLT-2 inhibitor (cardio-renal benefit) or DPP-4 inhibitor (weight-neutral) or sulfonylurea (cheapest, hypoglycaemia risk). Established cardiovascular disease or heart failure → SGLT-2 inhibitor preferred regardless of HbA1c. Significant weight excess → SGLT-2 or GLP-1 RA. Hypoglycaemia risk (elderly, frail, lone) → avoid sulfonylureas, prefer DPP-4 inhibitors or SGLT-2. Type 1 diabetes → basal-bolus insulin regimen (specialist-initiated, not catalogued here).
Important. Sudden hyperglycaemia with nausea, vomiting, abdominal pain → check for diabetic ketoacidosis (especially type 1 or SGLT-2 inhibitor user), urgent assessment. Severe hypoglycaemia with reduced consciousness → glucose / glucagon, 999. New diagnosis or significant control change requires HbA1c monitoring at 3 months. Lifestyle (diet, weight, activity, smoking cessation, BP and lipid control) remains the foundation of all diabetes care.
All MedsBase Diabetes products ship from WHO-GMP certified manufacturers with discreet packaging and are covered by our Reshipment Assurance Policy.
2026 buyer’s guide: See our shortlist Best Diabetes Medications 2026: 10 Top Picks Compared for ranked picks, comparison table, dosing notes and decision shortcut.